Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (myonuclei) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9372
Sealed predictions
- SGCG in dopamine neurons, braak+0.12 (p 0.768) → +0.59 (p 0.092)receipt 9380
Swarm cases
receipt 9380: SGCG in dopamine neurons, braak
- power
- full sample +0.38 (p 0.116, n 18), 95% CI -0.10 to +0.72. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.39 (p 0.105, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.46 (p 0.056, n 18). could be the mix.
- skeptic
- leave-one-out range +0.31 to +0.55, sign flips 0; without severely affected donors +0.38 (p 0.116, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SGCG in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts